Company profile: BioVie
1.1 - Company Overview
Company description
- Provider of biotechnological research and development focused on innovative therapies for the treatment of liver disease.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to BioVie
Precision Biologics
HQ: United States
Website
- Description: Provider of clinical-stage therapeutic and diagnostic products for the early detection and treatment of cancer, including monoclonal antibody drug candidates NEO-201 and Ensituximab (NEO-102), companion diagnostics (IHC and serum ELISA) to predict and monitor patient response, and clinical trials evaluating the efficacy of their therapeutic antibodies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Precision Biologics company profile →
OncoResponse
HQ: United States
Website
- Description: Provider of immuno-oncology therapies leveraging human immune responses, with a proprietary human-antibody discovery platform sourcing antibodies from elite responder patients; OR2805 targeting M2-like tumor-associated macrophages; collaboration with MD Anderson; and a preclinical pipeline of monoclonal antibodies addressing immunosuppression in the tumor microenvironment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OncoResponse company profile →
Everest Medicines
HQ: United States
Website
- Description: Provider of novel pharmaceutical therapies, including VELSIPITY (etrasimod), an oral once-daily S1P modulator for moderately to severely active ulcerative colitis; Nefecon, an oral delayed-release budesonide for primary IgA nephropathy in adults; Xerava (eravacycline), an IV antibiotic for complicated intra-abdominal infections; Zetomipzomib for autoimmune diseases; EVER001 for renal diseases; and an mRNA platform for vaccines and therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Everest Medicines company profile →
Barinthus Bio
HQ: United Kingdom
Website
- Description: Provider of clinical-stage immunotherapeutics and vaccines for infectious diseases and cancer, leveraging proprietary ChAdOx1/ChAdOx2 adenoviral vectors and MVA platforms to prime disease-specific T cells. Pipeline includes VTP-300 for chronic Hepatitis B, VTP-850 for prostate cancer, VTP-1000 for celiac disease, and the SNAP-TI platform to promote immune tolerance.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Barinthus Bio company profile →
Diatech Pharmacogenetics
HQ: Italy
Website
- Description: Provider of pharmacogenetics tests and precision medicine diagnostic solutions: Real Time PCR for variants of clinical interest in solid tumors and infectious diseases; Next Generation Sequencing equipment, libraries, and bioinformatics for SNPs, In/Del, CNV, and gene fusions in solid tumors; Pyrosequencing and fragment analysis for somatic or germline variants; and oncology equipment, kits, and software for analysis using MassArray technology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Diatech Pharmacogenetics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for BioVie
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to BioVie
2.2 - Growth funds investing in similar companies to BioVie
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for BioVie
4.2 - Public trading comparable groups for BioVie
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →